AtriCure (NASDAQ: ATRC) reported Q1 EPS of ($0.20), $0.04 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $54 million versus the consensus estimate of $52.45 million.

GUIDANCE:

Management is updating revenue guidance for 2019 to a range of $222 million to $228 million, corresponding to growth of 10% to 13% for the year, and maintaining expectations for positive full-year adjusted EBITDA between $0 and $3 million.

For earnings history and earnings-related data on AtriCure (ATRC) click here.